Table 2.
Patient characteristics, biomarker levels and diastolic function indices on TTE according to iron status in the HFpEF cohort.
| Iron Deficient | |||||
|---|---|---|---|---|---|
| Iron Replete | Total | Absolute | Functional | p-Value | |
| Female sex, n (%) | 39 (40%) | 79 (64%) | 59 (67%) | 20 (57%) | 0.0012 * |
| Age | 79.1 ± 9.2 | 79.1 ± 10.2 | 78.7 ± 10.2 | 82.8 ± 9.6 | 0.038 * |
| NYHA class, I/II/III/IV (%) | 2/6/34/44 | 1/9/45/57 | 1/3/32/44 | 0/6/13/13 | 0.19 |
| Length of stay, days | 9 ± 6 | 11 ± 7.7 | 11 ± 7 | 11 ± 9.5 | 0.036 * |
| CAD, n (%) | 36 (38%) | 35 (29%) | 27 (31%) | 8 (24%) | 0.30 |
| Hypertension, n (%) | 84 (87%) | 96 (81%) | 69 (81%) | 27 (82%) | 0.58 |
| Diabetes mellitus, n (%) | 35 (36%) | 37 (31%) | 26 (30%) | 11 (32%) | 0.67 |
| Obesity, n (%) | 46 (47%) | 60 (50%) | 47 (54%) | 13 (38%) | 0.28 |
| Active/past smoker, n (%) | 53 (58%) | 71 (59%) | 51 (59%) | 20 (59%) | 0.98 |
| CKD, n (%) | 50 (53%) | 44 (37%) | 26 (31%) | 18 (53%) | 0.008 * |
| Atrial fibrillation, n (%) | 50 (52%) | 61 (50%) | 41 (47%) | 20 (59%) | 0.50 |
| COPD, n (%) | 11 (12%) | 26 (22%) | 22 (27%) | 4 (12%) | 0.024 * |
| CRP | 13.3 ± 51.6 | 9.9 ± 26 | 7.5 ± 20.1 | 24 ± 48.6 | <0.001 * |
| BNP | 768 ± 710 | 585 ± 463 | 525 ± 461 | 1090 ± 236 | 0.46 |
| NT-proBNP | 3239 ± 6814 | 2389 ± 3174 | 2318 ± 2294 | 2515 ± 7058 | 0.12 |
| EF (%) | 60 ± 5 | 60 ± 7.5 | 60 ± 7.62 | 60 ± 7.5 | 0.97 |
CAD, coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association; CRP, C-reactive protein, BNP, brain-natriuretic peptide; NT-proBNP, N-terminal prohormone of BNP; EF, ejection fraction. * denotes p-value less than the significance threshold of <0.05.